Search Results
Results found for "terry kenakin"
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Kenakin’s answers. Kenakin noted, it wasn’t designed. Kenakin reveals the substrate strategy needed for credible DDI assessment. Kenakin reveals how teams choose between slow-off and true irreversible strategies. Why Terry’s Corner Give You The GPCR Pharmacology Insights You Need Terry’s Corner gives discovery scientists
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
Terry's Corner - New Course on Pharmacologic Models The latest Terry’s Corner unlocks clinical forecasting Kenakin. I wish Dr.
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
This week Terry's Corner unlocks a simple lever that separates signal from storytelling, moving programs Terry's Corner – Assay Volume Control in GPCR Drug Discovery This week in Terry’s Corner, you’ll learn 🎬 Plus New: Lesson Trailers Curious about Terry’s Corner before committing? Kenakin every last Thursday of the month at 12pm EST 7-day free trial to explore the corner 💎 $2999 Kenakin. I wish Dr.
- How Schild Analysis Protects Your Conclusions in GPCR Research
Terry’s Corner: Schild Analysis — Why It Matters Most assays show a clean rightward shift and we assume Kenakin breaks down why Schild analysis remains the gold standard for verifying true competition — and Premium Members get 50%+ discount when they join Terry’s Corner. Kenakin is a leading expert in the field. Kenakin is a masterful teacher and communicator.”
- Episode 86 of the Dr. GPCR podcast with Dr. Nicole (Nicki) Perry-Hauser is now available!
Nicole (Nicki) Perry-Hauser is now available What a fun chat! 📹Would you like to see the video?
- How Fast Does a Drug Work?
Kenakin’s latest lecture delivers exclusive, real-world insight designed to equip you to move beyond Kenakin’s kinetic insights help you translate assay readouts into actionable knowledge that keeps your But as Kenakin shows in this lecture, the reality is more nuanced, and mastering drug binding kinetics Kenakin’s lecture guides you through key questions that should shape your decision-making process: Are Kenakin gives you clear, practical guidance on when to look deeper and how to extract meaningful, operational
- The Five Traps of Ignoring Kinetics
Unlock “Kinetics: Advanced Applications” Only in Terry’s Corner Why Terry’s Corner Most pharmacology That’s where Terry’s Corner changes the game. experience Whether you’re validating assays, refining kinetic models, or deciding which leads to advance, Terry Subscribe to The Kenakin Brief today ➤
- Curve Shifts Don’t Lie, But Your Eyes Might
Unlock “Statistical Analysis” now Only in Terry’s Corner Why Terry’s Corner Your work demands clarity Terry’s Corner is designed to give you the edge. pharmacology experience Whether you’re validating assays, refining models, or deciding which leads to advance, Terry Subscribe to The Kenakin Brief today ➤ #ttest #ANOVA #poweranalysis #curvecomparison #ftest #assayvalidation
- From Snapshots to Predictions: Why Mechanism of Action Matters
This week in Terry's Corner you'll learn how model-based thinking helps you determine a drug’s mechanism Take the example Terry highlights: an agonist curve with a rightward shift and elevated baseline. Unlock “Mechanism of Action” now Only in Terry’s Corner Why Terry’s Corner When early choices determine Terry’s Corner is designed to give you the edge. Subscribe to The Kenakin Brief today ➤
- Understanding Enzyme Inhibition In GPCR Discovery Programs
Terry's Corner – How Enzyme Inhibition Shapes Every Discovery Program Every molecule meets an enzyme This week’s Terry’s Corner reframes inhibition not as background theory—but as a design lens for smarter Kenakin — October 30, 12 PM EST Bring your toughest pharmacology questions and join Dr. Kenakin live. Each session shapes next month’s lessons—so your challenges guide the content. Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost =
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
This week, Terry’s Corner takes you beyond curve shapes into the kinetic and mechanistic realities that Terry's Corner - Demystifying Antagonism: The Key to Precision Drug Discovery Understanding the nuances Kenakin’s expert guidance provides a clear framework for distinguishing these mechanisms and avoiding Premium Members get 50%+ discount when they join Terry’s Corner. Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner
- Why Opposing Processes Matter for Your Next GPCR Drug
Terry illustrates this with classic β-receptor partial agonists, showing how heart rate set-points under Terry’s Corner exists to fix that blind spot. Why Terry’s Corner Most pharmacology training freezes at equilibrium snapshots. Subscribe to The Kenakin Brief today ➤
- How System-Level GPCR Thinking Prevents Discovery Failures
Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses Kenakin’s AMA made the central point unmistakable: GPCR systems constantly reshape ligand behavior through Premium Members get 67% discount when they join Terry’s Corner in 2025 Sharpen your interpretation skills
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
Terry's Corner – Orthosteric vs. This week in Terry's Corner, we focuse on the distinction between orthosteric and allosteric mechanisms overdose risk without sacrificing meaningful efficacy. 🎬 Plus New: Lesson Trailers Curious about Terry Kenakin 💎 $2999/year — one conference cost = 12 months of expert training Premium Dr.
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
Terry’s Pharmacology Corner is built around that reality. take place: Thursday, February 26th at 12:00 PM EST You are invited to submit questions in advance to: terry Why Terry’s Pharmacology Corner Mechanistic understanding evolves. Terry’s Pharmacology Corner provides a structured environment for that evolution: Weekly advanced pharmacology
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail This week’s Terry’s Corner exposes the unseen physiological “opponents” your molecule faces—and how
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Terry W. Moore, was most definitely a success.
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
While these signaling pathways are highly interconnected, they can also be regulated independently (Kenakin Kenakin, T. (2019). Biased receptor signaling in drug discovery.
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
In: Kenakin TP, editor A Pharmacology Primer (Sixth Edition). Kenakin TP. Kenakin TP. Kenakin T. The mass action equation in pharmacology. Kenakin T. Biased Receptor Signaling in Drug Discovery.
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
Kenakin and Hoare on ' Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
Kenakin's upcoming course. We aim to make education accessible to all!
- GPCR Buzz of the Week | Sep 23 - 29, 2024
Kenakin's upcoming course. Our goal is to ensure that education is within reach for everyone!
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
Kenakin's upcoming course. We aim to make education accessible to all!
- 📰 GPCR Weekly News, May 6 to 12, 2024
Kenakin will be back with two back-to-back classes.
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
extensive experimental datasets and in vivo validation which does not always align with in vitro evidence (Kenakin
- Decoding β-Arrestins: from Structure to function
kinases, emphasizing their role as hubs for increasing local effector concentrations near active GPCRs (Perry-Hauser
- Ode to GPCRs
Ferry, G. Paul Greengard (1925–2019).
























